Founded by ophthalmic innovator Sean Ianchulev, MD MPH, Iantrek develops micro-interventional technologies for glaucoma surgery and advances bio-interventional treatment through the uveoscleral pathway. Its portfolio includes AlloFlo Uveo scleral allograft tissue, the AlloSert Uveo delivery instrument, and C-Rex, which combines canaloplasty and goniotomy in one motion. The company’s CREST study has followed more than 450 eyes across 16 locations for at least two years, with findings reported in peer-reviewed publications.
Avisi Technologies, IncFounded through the University of Pennsylvania’s Y-Prize program in 2017, Avisi Technologies develops nanotechnology-enabled ophthalmic devices for glaucoma, including its investigational VisiPlate aqueous shunt. The Redwood City company combines materials science, ophthalmology and MEMS microfabrication to create ultrathin implants intended to lower eye pressure, while its VisiPlate technology advances through clinical research.PHILADELPHIA, PA
CIMA Technology IncCIMA Technology Inc. manufactures and distributes ophthalmic products for cataract surgery and has focused for more than 25 years on supplying intraocular lenses and ophthalmic viscosurgical devices internationally. Headquartered in Pennsylvania, the company says its US-made products are developed with ophthalmologists and non-governmental organizations for international markets.PITTSBURGH, PA
Peregrine Surgical LLCFounded in 1991, Peregrine Surgical LLC makes and develops single-use ophthalmic and vitreoretinal surgical devices for OEM and private-label partners. Its roots in fiber optics show in products such as illuminated laser probes and light pipes, while its in-house development and packaging services help medical-device companies move products from prototype to market. Peregrine performs product development to meet U.S. Code of Federal Regulations Title 21 and ISO 13485 requirements.NEW BRITAIN, PA
Clerio Vision, IncBorn from Nobel Prize-winning University of Rochester research that began in 2003, Clerio Vision develops medical-device platforms for non-invasive vision correction. Its LIRIC technology uses ultrashort laser pulses to write optical prescriptions directly into lens materials or corneal tissue without removing material, with applications spanning contact lenses, myopia control, implanted lenses and refractive correction. The Rochester company is development-stage and has completed first-in-human LIRIC trials while building a patent portfolio of more than 80 U.S. patents.ROCHESTER, NY